1736. Xeruborbactam (QPX) Potentiates the Activity of Multiple β-Lactams Against Highly Resistant Pseudomonas aeruginosa to a Greater Degree than Other β-Lactamase Inhibitors. (15th December 2022)

• Record Type: Journal Article
• Authors: Fleres, Giuseppe; Newbrough, Anthony; Hao, Binghua; Chen, Liang; Shields, Ryan K; Clancy, Cornelius J; Nguyen, Minh-Hong
• Is Part Of: Open forum infectious diseases. Volume 9:(2022)Supplement 2
• Publication Date: 2022-12-15
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac492.1366
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: Pseudomonas aeruginosa (PA) is an important pathogen notorious for antibiotic resistance. Xeruborbactam (QPX) is a potent ultra-broad-spectrum boronic acid β-lactam inhibitor (BLI) that, in combination with selected BL antibiotics, has excellent in vitro activity against carbapenem-resistant Enterobacterales (CRE), and Acinetobacter baumanii or PA producing class A/B or D carbapenemases. We evaluated QPX in combination with anti-pseudomonal BLs against clinical PA isolates from tertiary care US hospitals. Methods: We tested PA clinical isolates resistant to ≥1 BL (imipenem (IMP), meropenem (MEM), cefepime (FEP), piperacillin-tazobactam (PIP-TAZ), aztreonam (ATM), ceftolozane-tazobactam (TOL-TZP), ceftazidime-avibactam (CZA), IMI-relebactam (IMI-REL), MEM-vaborbactam (MVB)) against QPX (in fixed concentration of 8 µg/mL) combined with anti-pseudomonal BLs. We performed whole-genome sequencing on isolates using the MiSeq platform (Illumina). Results: Antibiograms and resistance determinants of 77 isolates tested to date are summarized in Figs 1, 2. 91% of isolates were CR; 43%, 58% and 61% were resistant to CZA, IMI-REL and MVB, respectively. No isolates produced class A/B/D carbapemases. All except 2 isolates carried PDC variants. 92% either had oprD porin single nucleotide polymorphism (SNP) or deletions. mutS mutations (present in 23% of isolates) were associated with resistance to IPM/QPX (p=.04), but not TOL-QPX or PIP-QPX. Addition of QPX significantly reduced MIC50 of IPM (32-fold), PIP (16-fold), FEP and ATM (4-fold) (all p< .0001, Fig 3). Addition of QPX to MEM or TOL reduced MIC50 by 2-fold (p=.02, p< .0001). QPX reduced IMP and PIP MICs more than did REL (32 vs 8-fold, p< .0001) or TZP (16 vs nil, p=.0007), respectively. Addition of QPX reduced BL resistance, especially for TOL, PIP and IMP (Fig 4). We identified factors associated with BL/QPX resistance by logistic regression; for IMP/QPX: IMP resistance (p=.001), SNP in mexB (p=.01); for TOL/QPX: TOL resistance (p=.02); for PIP/QPX (SNP in mexR and mexB (p=.03). Conclusion: QPX enhanced the activity of BLs, especially TOL and PIP, against PA with baseline resistance to BL, more so than other BLIs. TOL/QPX and PIP/QPX are less impacted by PA efflux and porin mutations than IMP/QPX. Disclosures: Cornelius J. Clancy, MD, receives research funding paid to his institution from Astellas and Merck: Grant/Research Support|serves as an advisory Board member for Astellas, Cidara, and Scynexis, served on the advisory board for Merck, Qpex Biopharma, and Shionogi: Advisor/Consultant|Venatorx and Needham & Associates: Advisor/Consultant.